Egetis Therapeutics AB (publ) (BST:P0F)
Germany · Delayed Price · Currency is EUR | Market Cap | 412.37M +120.3% |
| Revenue (ttm) | 5.96M +39.5% |
| Net Income | -36.61M |
| EPS | -0.09 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 33.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.8570 |
| Previous Close | 0.8570 |
| Day's Range | 0.8500 - 0.8810 |
| 52-Week Range | 0.3770 - 0.8800 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Egetis Therapeutics AB
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Thera... [Read more]
Financial Performance
In 2025, Egetis Therapeutics AB's revenue was 62.40 million, an increase of 35.36% compared to the previous year's 46.10 million. Losses were -342.50 million, -0.32% less than in 2024.
Financial numbers in SEK Financial StatementsNews
Egetis Therapeutics AB Transcript: FDA announcement
EMCITATE received FDA approval as the first treatment for MCT8 deficiency, covering all ages and supported by robust clinical data. Commercial launch is set for 8-10 weeks, with pricing at $950,000 annually and a focus on broad access, especially for pediatric Medicaid patients.
Egetis Therapeutics AB Press release: FDA announcement
Egetis Therapeutics AB issued a press release on September 29, 2026, disclosing material business information to investors.
Egetis Therapeutics AB Slides: FDA announcement
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on September 29, 2026.
Egetis Therapeutics AB Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is poised for a major milestone with the upcoming U.S. PDUFA date for its lead rare disease therapy, supported by robust clinical data and a strong launch infrastructure. European expansion is underway, with Germany showing rapid patient identification growth, and global partnerships broadening access.
Egetis Therapeutics AB Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted robust clinical data and commercial progress for tiratricol in MCT8 deficiency, with a strong U.S. launch strategy, expanding patient identification, and global partnerships. RTH-beta represents a significant pipeline opportunity, with pivotal trials planned for next year.
Egetis Therapeutics AB Slides: Corporate presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on August 26, 2026.
Egetis Therapeutics AB Earnings Call Transcript: Q2 2026
Emcitate's U.S. NDA received FDA priority review with a PDUFA date of September 28, 2026, and launch preparations are complete. Q2 revenue grew 23% year-over-year, with strong progress in Europe and expanded international partnerships. Cash position strengthened by a SEK 350 million share issue.
Egetis Therapeutics AB Quarterly report: Q2 2026
Egetis Therapeutics AB has published its Q2 2026 quarterly earnings report on August 21, 2026.
Egetis Therapeutics AB Slides: Q2 2026
Egetis Therapeutics AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 21, 2026.
Egetis Therapeutics AB Slides: Corporate presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Egetis Therapeutics AB Slides: Corporate presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Egetis Therapeutics AB Earnings Call Transcript: Q1 2026
FDA accepted NDA for Emcitate with priority review and a Q4 2026 U.S. launch expected. Q1 revenue grew 9% year-over-year, and SEK 350 million was raised to support commercialization and pipeline expansion. European sales momentum continues despite reimbursement challenges.
Egetis Therapeutics AB Quarterly report: Q1 2026
Egetis Therapeutics AB has published its Q1 2026 quarterly earnings report on April 29, 2026.
Egetis Therapeutics AB Slides: Q1 2026
Egetis Therapeutics AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Egetis Therapeutics AB Slides: Corporate presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on April 7, 2026.
Egetis Therapeutics AB Slides: Corporate presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on March 16, 2026.
Egetis Therapeutics AB Transcript: Leerink Global Healthcare Conference 2026
Emcitate achieved EU approval and is under FDA review, supported by robust mortality and clinical data. U.S. commercialization efforts are ramping up, with significant patient identification and a potential $1M annual price point. Indication expansion and new IP strategies are underway.
Egetis Therapeutics AB Slides: Corporate presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Egetis Therapeutics AB Transcript: Fireside chat
The CEO shared insights on rare disease drug development, highlighting progress in diagnosis, regulatory milestones, and commercialization strategies. Emcitate's approval in Europe and pending U.S. launch mark significant achievements, with further pipeline expansion and profitability expected within a year of U.S. entry.
Egetis Therapeutics AB Earnings Call Transcript: Q4 2025
Emcitate revenue grew 40% year-over-year to SEK 62.4 million, driven by EU launch and expanded access. U.S. NDA submission completed, with FDA decision expected in September 2026 and launch preparations underway. Patient identification in the U.S. surpassed 140, with further growth anticipated.
Egetis Therapeutics AB Annual report: Q4 2025
Egetis Therapeutics AB has published its Q4 2025 annual report on February 26, 2026.
Egetis Therapeutics AB Quarterly report: Q4 2025
Egetis Therapeutics AB has published its Q4 2025 quarterly earnings report on February 26, 2026.
Egetis Therapeutics AB Slides: Q4 2025
Egetis Therapeutics AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
Egetis Therapeutics AB Slides: Corporate Presentation
Egetis Therapeutics AB has posted slides in relation to its latest quarterly earnings report, which was published on December 2, 2025.
Egetis Therapeutics AB Earnings Call Transcript: Q3 2025
FDA Breakthrough Therapy designation and positive ReTRIEVE study results support Triac's NDA submission for MCT8 deficiency, with U.S. launch preparations underway. Revenue and cash position improved year-over-year, bolstered by a SEK 172 million rights issue.